Based on the paradigm that OV therapy generates potent antitumor T cell responses, VSV’s ability to increase CD8 T cell infiltration of the cold B16 melanoma tumor suggested that it may be an ideal candidate to be combined with immune checkpoint blockade (ICB) therapy. This evidence concerns the gene CD8A and neoplasm.